CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19
08 mars 2021 06h05 HE
|
CytoDyn Inc.
U.S. FDA Reviewing Protocol for More COVID-19 Critical Patients to be Enrolled to Support Potential EUA CytoDyn submitted protocol to U.S. FDA for immediate enrollment of 140 critical COVID-19...
CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab
08 mars 2021 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, March 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19
06 mars 2021 20h40 HE
|
CytoDyn Inc.
U.S. FDA Reviewing Protocol for More COVID-19 Critical Patients to be Enrolled to Support Potential EUA CytoDyn submitted protocol to U.S. FDA for immediate enrollment of 140 critical COVID-19...
CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K., Canada, Philippines and Brazil
05 mars 2021 18h29 HE
|
CytoDyn Inc.
VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab
05 mars 2021 17h47 HE
|
CytoDyn Inc.
VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn Files Form S-3 to Replace Expiring Shelf Registration Statement
03 mars 2021 17h27 HE
|
CytoDyn Inc.
VANCOUVER, Washington, March 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients
22 févr. 2021 06h00 HE
|
CytoDyn Inc.
CytoDyn expects to release CD12 data and complete discussions with various regulatory agencies within 2 to 3 weeks VANCOUVER, Washington, Feb. 22, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:...
Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use
29 janv. 2021 16h01 HE
|
CytoDyn Inc.
CytoDyn will dedicate at least 200,000 vials (100,000 doses) of leronlimab from its inventory to Chiral Pharma Corp. for potential sales in the Philippines VANCOUVER, Washington, Jan. 29, 2021 ...
REMINDER: CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries
04 janv. 2021 06h00 HE
|
CytoDyn Inc.
Correction to inclusion/exclusion criteria for eIND authorization VANCOUVER, Washington, Jan. 04, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage...
CytoDyn Announces Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity
31 déc. 2020 00h49 HE
|
CytoDyn Inc.
Manuscript entitled: “Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab,” by Nicholas J. Agresti, M.D. ...